ClinicalTrials.gg
CompletedNCT05757713PETITE-T1DUpdated Sep 29, 2026

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

A Phase 4 interventional study of teplizumab in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 10 sites in United States. Open to participants aged 0 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
0 Years to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
8th of 11
23 · median 60
Started
2023
the only one that year
Phase 4
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
3 of 11
Sanofi

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 8th largest by enrollment, is the only one that started in 2023, is the only one in phase 4, and was the 8th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 0 Years to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.

Read the detailed description

This is a single-arm, non-randomized, open-label, multicenter study in the U.S. to assess the safety and pharmacokinetics of teplizumab in pediatric participants with Stage 2 type 1 diabetes (T1D) (two T1D-related autoantibodies and dysglycemia) who are 0 to \<8 years of age. Anti-drug antibodies/neutralizing antibodies (ADA/NAb) will also be assessed.

Approximately 20 participants will be enrolled. The regimen consists of an intravenous infusion of teplizumab once daily for 14 consecutive days. The study duration for each individual may last up to approximately 26 months.

The safety, tolerability, PK, ADA, and T1D clinical feature data will be summarized using descriptive statistics.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Type 1 diabetes
  • Stage 2
  • Pediatric type 1 diabetes
  • T1D
  • At-risk
04

Who can participate

Ages eligible
0 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is a male or female 0 to \< 8 years of age, inclusive, at Day 1
  2. Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia)

Exclusion criteria

Exclusion Criteria:

  1. Participant has any disease other than T1D with the exception of stable thyroid or celiac disease
  2. Has an active infection and/or fever
  3. Has a history of or serologic evidence at screening of current or past infection with (HIV), virus (HBV), or virus (HCV).
  4. Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    teplizumab injection

    teplizumab injection, sterile solution for intravenous use

    Biological: teplizumab

Interventions

  • Biologicalteplizumab

    CD3-directed humanized monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)

    Safety and tolerability endpoint

    Time frame: Through 104 Weeks

Secondary outcomes

  1. Serum concentrations of teplizumab

    Pharmacokinetic (PK) endpoint

    Time frame: Sparse PK samples between Days 1 and 28

  2. Anti-drug antibody (ADA) titers and presence of neutralizing antibodies (Nab)

    Immunogenicity endpoint

    Time frame: Through 104 weeks

  3. CD3 receptor occupancy

    To assess the effects of teplizumab on cluster of differentiation 3 (CD3) receptor occupancy

    Time frame: Days 1 and 9

07

Study locations

10 sites
  • UCSF Medical Center Site Number : 107
    San Francisco, California 94143, United States
  • Barbara Davis Center for Diabetes Site Number : 102
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine Site Number : 101
    New Haven, Connecticut 06511, United States
  • Centricity Research Site Number : 104
    Columbus, Georgia 31904, United States
  • Indianapolis University Health Riley Hospital for Children Site Number : 110
    Indianapolis, Indiana 46202, United States
  • UBMD Pediactrics Site Number : 105
    Buffalo, New York 14203, United States
  • Children's Hospital of Philadelphia Site Number : 108
    Philadelphia, Pennsylvania 19104, United States
  • Sanford Diabetes and Thyroid Clinic Site Number : 106
    Sioux Falls, South Dakota 57105, United States
  • Vanderbilt Univerity Medical Center Site Number : 109
    Nashville, Tennessee 37232, United States
  • MulitCare Institute for Research & Innovation Site Number : 103
    Tacoma, Washington 98405, United States
08

References and documents

Publications

  • Gitelman SE, Simmons K, Sherr JL, Leichter SB, Quattrin T, Russell WE, Sunil B, Willi SM, Knecht LA, Niemoeller E, Licaj I, Schmider W, Miller D, DiMeglio LA. Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes. Diabetologia. 2026 Feb;69(2):330-342. doi: 10.1007/s00125-025-06586-1. Epub 2025 Nov 6. PubMed 41196293 ↗
  • Novograd J, Frishman WH. Teplizumab Therapy to Delay the Onset of Type 1 Diabetes. Cardiol Rev. 2024 Nov-Dec 01;32(6):572-576. doi: 10.1097/CRD.0000000000000563. Epub 2023 May 9. PubMed 37158990 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Aug 2026, 37 months.

Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Mar 7, 2023
StartActual
Jul 25, 2023
Primary completionActual
Aug 28, 2026
CompletionActual
Aug 28, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Primary completion
Aug 27, 2026→Aug 28, 2026 (actual)
Sep 29, 2026
Study completion
Aug 27, 2026→Aug 28, 2026 (actual)
Sep 29, 2026
Enrollment
20 (estimated)→23 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Primary completion Aug 27, 2026→Aug 28, 2026 (now actual)
    Study completion Aug 27, 2026→Aug 28, 2026 (now actual)
    Enrollment 20 (estimated)→23 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05757713
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Jul 25, 2023
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Sep 29, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion